← Back to Clinical Trials
Recruiting NCT06219863

NCT06219863 Harness-based Mobility Intervention for Infants With Down Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06219863
Status Recruiting
Phase
Sponsor Boston University Charles River Campus
Condition Down Syndrome
Study Type INTERVENTIONAL
Enrollment 6 participants
Start Date 2024-07-31
Primary Completion 2025-08-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 2 Years
Study Type INTERVENTIONAL
Interventions
Body weight supported harness

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 6 participants in total. It began in 2024-07-31 with a primary completion date of 2025-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The emergence of crawling and walking is significantly delayed in infants with Down syndrome (DS), but the development of independent mobility provides infants with new opportunities for exploring the environment and interacting with objects and people that are important foundations for early learning. Increasing infant mobility early in development with body weight supported harness systems may support infant exploration, communication, and social interaction. This project will set the stage for the first clinical trial of a mobility-related intervention specifically tailored for infants with DS by testing the feasibility of harness systems with infants and families and identifying measures that will serve as primary outcome variables. Upon completion of this pilot project, necessary preliminary data and experience required for an in-home, high-impact clinical trial for infants with DS will have been obtained.

Eligibility Criteria

Inclusion Criteria: * confirmed diagnosis of Trisomy 21 * younger than 24 months * English is the primary language of the home (due to use of standardized language assessments normed on English-speaking children) * able to sit without support * not yet taking any independent steps. Exclusion Criteria: * Mosaic or Translocation Down syndrome * severe, uncontrolled medical problems (including heart disease with cardiovascular instability, uncontrolled epilepsy) * severe uncorrected hearing or vision impairments

Contact & Investigator

Central Contact

Anna Donato

✉ buicl.studies@gmail.com

📞 (774) 275-3321

Principal Investigator

Jana Iverson, PhD

PRINCIPAL INVESTIGATOR

Boston University

Frequently Asked Questions

Who can join the NCT06219863 clinical trial?

This trial is open to participants of all sexes, up to 2 Years, studying Down Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06219863 currently recruiting?

Yes, NCT06219863 is actively recruiting participants. Contact the research team at buicl.studies@gmail.com for enrollment information.

Where is the NCT06219863 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT06219863 clinical trial?

NCT06219863 is sponsored by Boston University Charles River Campus. The principal investigator is Jana Iverson, PhD at Boston University. The trial plans to enroll 6 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology